Adma Biologics (ADMA) Other financing activities (2011 - 2026)

Adma Biologics (ADMA) has 8 years of Other financing activities data on file, last reported at $430000.0 in Q4 2025.

• Quarterly Other financing activities rose 106.1% year-over-year to $430000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
• Other financing activities climbed to $430000.0 in Q4 2025, from $389000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $5.7 million in Q3 2024 to a low of -$7.1 million in Q4 2024.
• A 4-year average of $490785.7 and a median of $417281.0 in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2023 — Other financing activities jumped 11011.11% — and 2024, when it slumped 88237.5%.
• Tracing ADMA's Other financing activities over 4 years: stood at $72.0 in 2022, then jumped by 11011.11% to $8000.0 in 2023, then tumbled by 88237.5% to -$7.1 million in 2024, then surged by 106.1% to $430000.0 in 2025.
• The last three Other financing activities figures came in at $430000.0 (Q4 2025), $389000.0 (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.